submitted the changes in securities holding report (59-2) Reports on Acquisition or Disposition of Securities (246-2) Financial Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income
holding report (59-2) Reports on Acquisition or Disposition of Securities (246-2) Financial Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income (MB.) 6M/2022 (01/01/22 -30/06/22
-2) Financial Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income (MB.) 6M/2022 (01/01/22 -30/06/22) 6M/2021 (01/01/21 -30/06/21) 2021 (01/01/21 -31/12/21) 2020 (01
Securities (246-2) Financial Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income (MB.) 6M/2022 (01/01/22 -30/06/22) 6M/2021 (01/01/21 -30/06/21) 2021 (01/01/21 -31/12/21
subsidiary for Quarter 1 of 2019 ending on 31 March 2019 as follows; Statements of Comprehensive Income Revenue from medical treatment The Company generated the revenue from medical treatment for the 1st
' Remuneration (23,084) (16,557) 6,527 (39.42) Loss on impairment of intangible assets (22,140) - (22,140) 100.00 Loss on impairment of goodwill (92,361) - (92,361) 100.00 Profit (loss) from Exchange Rate (6,254
Comprehensive Income (MB.) 2021 (01/01/21 -31/12/21) 2020 (01/01/20 -31/12/20) 2019 (01/01/19 -31/12/19) 2018 (01/01/18 -31/12/18) Accounting Type Consolidate Consolidate Consolidate Consolidate
Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income (MB.) 2021 (01/01/21 -31/12/21) 2020 (01/01/20 -31/12/20) 2019 (01/01/19 -31/12/19) 2018 (01/01/18 -31/12/18
) Reports on Acquisition or Disposition of Securities (246-2) Financial Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income (MB.) 2021 (01/01/21 -31/12/21) 2020 (01/01/20 -31
of Securities (246-2) Financial Statements (Concise Version) 5/ Full Version Statement of Comprehensive Income (MB.) 2021 (01/01/21 -31/12/21) 2020 (01/01/20 -31/12/20) 2019 (01/01/19 -31/12/19